Related Experiment Video

Updated: Aug 29, 2025

Nasal Brushing Sampling and Processing Using Digital High Speed Ciliary Videomicroscopy – Adaptation for the COVID-19 Pandemic
09:03

Nasal Brushing Sampling and Processing Using Digital High Speed Ciliary Videomicroscopy – Adaptation for the COVID-19 Pandemic

Published on: November 7, 2020

4.9K

Resolution of COVID-19 induced anosmia following treatment with ST266

Devica L Bhutani1, Ahmara G Ross1,2, Amanda Y Lehman1

  • 1Department of Ophthalmology, Scheie Eye Institute, University of Pennsylvania, Philadelphia, PA, USA.

Otolaryngology Case Reports
|September 12, 2022
PubMed
Abstract

Insights

A novel secretome therapy (ST266) successfully treated persistent anosmia (loss of smell) in a patient with long COVID. This intranasal treatment offers potential for restoring smell function in patients with olfactory dysfunction.

Area of Science:

  • Neuroscience
  • Ophthalmology
  • Pharmacology

Background:

  • Persistent anosmia is a common and debilitating symptom following COVID-19 infection.
  • Current treatments for post-COVID olfactory dysfunction are limited, highlighting the need for novel therapeutic approaches.
  • Restoring the sense of smell has significant potential to improve patients' quality of life.

Observation:

  • A clinical trial investigated the safety of intranasal secretome therapy (ST266) in glaucoma suspects.
  • A 46-year-old female patient with over a year of COVID-19-induced anosmia participated in the trial.
  • The patient received bilateral intranasal ST266 for 28 days.

Findings:

  • The patient experienced complete resolution of her long-standing anosmia after the 28-day treatment course.
  • This case report demonstrates the efficacy of ST266 in resolving persistent post-COVID olfactory dysfunction.
  • The intranasal administration of ST266 was associated with the restoration of smell.

Implications:

  • Acellular secretome therapy (ST266) shows promise for treating COVID-19-induced anosmia.
  • Further research is necessary to validate these findings and explore ST266's therapeutic potential.
  • This novel therapy could offer a new treatment option for patients suffering from smell loss.
Keywords:
AnosmiaCOVID-19Intranasal therapyOlfactory dysfunctionST266

More Related Videos

Neuro-rehabilitation Approach for Sudden Sensorineural Hearing Loss09:44

Neuro-rehabilitation Approach for Sudden Sensorineural Hearing Loss

Published on: January 25, 2016

19.3K
Infection of Primary Nasal Epithelial Cells Grown at an Air-Liquid Interface to Characterize Human Coronavirus-Host Interactions09:02

Infection of Primary Nasal Epithelial Cells Grown at an Air-Liquid Interface to Characterize Human Coronavirus-Host Interactions

Published on: September 22, 2023

1.5K

Related Concept Videos

Olfactory Receptors: Location and Structure01:03

Olfactory Receptors: Location and Structure

The process of olfaction, also known as the sense of smell, is a sophisticated chemical response system. The specialized sensory neurons that facilitate this process, known as olfactory receptor neurons, are situated in an upper segment of the nasal cavity, known as the olfactory epithelium. Olfactory sensory neurons are bipolar, with their dendrites extending from the epithelium's apex into the mucus that lines the nasal cavity. Airborne molecules, when inhaled, traverse the olfactory...
9.5K
Acute Pharyngitis01:30

Acute Pharyngitis

Introduction
Acute pharyngitis is the inflammation of the back of the throat (pharynx), commonly resulting in a sore throat. It is a frequently encountered condition that prompts individuals to seek medical advice.
Classification
Acute pharyngitis can be categorized based on its underlying cause:
1.4K
Taste Buds and Receptors01:20

Taste Buds and Receptors

Gustation, or the sense of taste, is intrinsically linked to the anatomical structures located on the tongue. This organ's surface, along with the entirety of the oral cavity, is adorned with stratified squamous epithelium. Evident on the tongue are elevated structures known as papillae (singular = papilla), which house the mechanisms for the transduction of gustatory stimuli. Four distinct types of papillae exist, each identified by their unique morphological attributes: the circumvallate,...
2.6K
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids01:21

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
361
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
308